share_log

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

福泰制药 | 144:拟议出售证券
美股sec公告 ·  05/20 15:36
Moomoo AI 已提取核心信息
Vertex Pharmaceuticals Inc. officer and director, Kewalramani Reshma, is set to sell 15,202 shares of common stock on 05/20/2024, with an aggregate market value of approximately $6,795,294. The shares to be sold were acquired through restricted stock vesting as part of compensation from the issuer on various dates ranging from 02/10/2023 to 02/24/2024. The total number of shares acquired through these transactions was 15,202, matching the number of shares intended for sale. No securities sales have been reported in the past three months prior to the notice date of 05/20/2024.
Vertex Pharmaceuticals Inc. officer and director, Kewalramani Reshma, is set to sell 15,202 shares of common stock on 05/20/2024, with an aggregate market value of approximately $6,795,294. The shares to be sold were acquired through restricted stock vesting as part of compensation from the issuer on various dates ranging from 02/10/2023 to 02/24/2024. The total number of shares acquired through these transactions was 15,202, matching the number of shares intended for sale. No securities sales have been reported in the past three months prior to the notice date of 05/20/2024.
Vertex Pharmicals Inc.高管兼董事Kewalramani Reshma定于2024年5月20日出售15,202股普通股,总市值约为6,795,294美元。待出售的股票是通过限制性股票归属收购的,作为发行人补偿的一部分,日期为2023年10月2日至2024年2月24日。通过这些交易获得的股票总数为15,202股,与拟出售的股票数量相当。在2024年5月20日通知日期之前的过去三个月中,没有报告任何证券销售情况。
Vertex Pharmicals Inc.高管兼董事Kewalramani Reshma定于2024年5月20日出售15,202股普通股,总市值约为6,795,294美元。待出售的股票是通过限制性股票归属收购的,作为发行人补偿的一部分,日期为2023年10月2日至2024年2月24日。通过这些交易获得的股票总数为15,202股,与拟出售的股票数量相当。在2024年5月20日通知日期之前的过去三个月中,没有报告任何证券销售情况。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息